This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Relmada Therapeutics’s 8K filing here.
About Relmada Therapeutics
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
Recommended Stories
- Five stocks we like better than Relmada Therapeutics
- How to Invest in Insurance Companies: A Guide
- How to Master Trading Discipline: Overcome Emotional Challenges
- ETF Screener: Uses and Step-by-Step Guide
- Does China Investigation Change NVIDIA’s Outlook; Yes, No, Maybe?
- How to Evaluate a Stock Before Buying
- Is Marvell Technology Chipping Away at NVIDIA’s Market Lead?
